Skip to main content
. 2017 Dec 8;17:213. doi: 10.1186/s12883-017-0985-0

Table 1.

Overview of data sources characteristics (n = 53)

Characteristics Included Status Country Study population
All (n = 53) Ongoing (n = 16) Completed (n = 37) USA (n = 42) International (n = 11) Parkinson cohort
(n = 25)
“Generic” cohort
(n = 28)
Size (number of Parkinsonian patients)
0-500 42 (79) 11 (69) 31 (84) 37 (88) 5 (45) 22 (88) 20 (71)
500-1000 7 (13) 4 (25) 3 (8) 3 (7) 4 (36) 3 (12) 4 (14)
>1000 4 (8) 1 (6) 3 (8) 2 (5) 2 (18) 0 (0) 4 (14)
Duration of follow-up (years)
<2 6 (11) 0 (0) 6 (16) 4 (10) 2 (18) 4 (16) 2 (7)
2-5 20 (38) 4 (25) 16 (43) 16 (38) 4 (36) 13 (52) 7 (25)
≥5 27 (51) 12 (75) 15 (41) 22 (52) 5 (45) 8 (32) 19 (68)
Dimensions assessed
Motor and neurological 46 (87) 12 (75) 34 (92) 36 (86) 10 (91) 25 (100) 21 (75)
Cognition 41 (77) 13 (81) 28 (76) 36 (86) 5 (45) 17 (68) 24 (86)
Psychiatric symptoms 38 (72) 10 (63) 28 (76) 30 (71) 8 (73) 19 (76) 17 (61)
Activities of daily living 22 (42) 6 (38) 16 (43) 15 (36) 7 (64) 12 (48) 10 (36)
Sleep quality 11 (21) 4 (25) 7 (19) 5 (12) 6 (55) 2 (8) 9 (32)
Quality of life 9 (17) 4 (25) 5 (14) 5 (12) 4 (36) 6 (24) 3 (11)
Autonomic symptoms 7 (13) 4 (25) 3 (8) 3 (7) 4 (36) 0 (0) 7 (25)
Other 20 (38) 9 (56) 11 (30) 13 (31) 7 (64) 8 (32) 12 (43)
Other assessments
Current medications 43 (81) 13 (81) 30 (81) 32 (76) 11 (100) 22 (88) 21 (75)
Comorbidities 42 (79) 14 (88) 28 (76) 31 (74) 11 (100) 20 (80) 22 (79)
Medical imaging 19 (36) 6 (40) 13 (34) 11 (26) 8 (73) 6 (24) 13 (46)
Genetics 16 (30) 6 (38) 10 (27) 10 (24) 6 (55) 3 (12) 13 (46)
Caregiver burden 6 (11) 4 (27) 2 (5) 5 (12) 1 (9) 4 (16) 2 (7)
Healthcare costs 1 (2) 1 (7) 0 (0) 0 (0) 1 (9) 1 (4) 0 (0)

Data are shown as absolute frequency (percentage)